Process Development

Oct 30, 2018
By BioPharm International Editors
The acquisition will allow Lonza to further develop technology for scalable autologous cell-therapy manufacturing.
Oct 01, 2018
By BioPharm International Editors
The companies partnered to build a 500-L single-use pilot-scale plant for biologics production.
Sep 27, 2018
By BioPharm International Editors
GE Healthcare, Cobra Biologics, and the Centre for Process Innovation (CPI) have entered into a collaboration to advance manufacturing of adeno-associated virus vectors for gene therapy.
Sep 20, 2018
By BioPharm International Editors
The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.
Sep 01, 2018
BioPharm International
Automation can improve many aspects of bioprocessing, but several hurdles must be overcome before the full range of benefits can be realized.
Aug 08, 2018
By BioPharm International Editors
Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
Aug 06, 2018
By BioPharm International Editors
Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.
Aug 01, 2018
BioPharm International
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
Jul 19, 2018
By BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 12, 2018
By BioPharm International Editors
The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.
native1_300x100
lorem ipsum